MSA Advisors LLC Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• MSA Advisors LLC significantly increased its stake in Eli Lilly by 212.5% during the first quarter, now holding 2,500 shares worth approximately $2.06 million.
• Eli Lilly recently declared a quarterly dividend of $1.50 per share, with a 1.0% yield, to be paid on September 10th.
• The company reported a strong quarterly earnings result with an EPS of $6.31, exceeding estimates and showing a 37.6% year-over-year revenue growth of $15.56 billion.

MSA Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 212.5% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,500 shares of the company's stock after purchasing an additional 1,700 shares during the period. Eli Lilly and Company comprises approximately 0.5% of MSA Advisors LLC's portfolio, making the stock its 14th biggest holding. MSA Advisors LLC's holdings in Eli Lilly and Company were worth $2,065,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. WestEnd Advisors LLC boosted its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Citizens National Bank Trust Department boosted its stake in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at $40,000. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $43,000. Finally, O Brien Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after acquiring an additional 12 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. UBS Group decreased their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price on the stock. Finally, Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $984.41.

Eli Lilly and Company Trading Down 2.5%

Shares of Eli Lilly and Company stock traded down $15.71 during trading hours on Friday, reaching $625.15. The stock had a trading volume of 14,089,857 shares, compared to its average volume of 5,397,104. The firm has a 50 day simple moving average of $774.10 and a two-hundred day simple moving average of $799.34. The firm has a market capitalization of $591.68 billion, a price-to-earnings ratio of 40.86, a P/E/G ratio of 0.87 and a beta of 0.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business posted $3.92 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Insider Activity at Eli Lilly and Company

In related news, Director Jamere Jackson bought 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.